ГЕПАТИТ ДЕЛЬТА: ЭТИОЛОГИЯ, КЛИНИКА, ДИАГНОСТИКА, ТЕРАПИЯ (ЛЕКЦИЯ ДЛЯ ПРАКТИЧЕСКИХ ВРАЧЕЙ)

A significant part of liver disease, once considered the result of infection by hepatitis B virus (HBV), are the result of infection HBV, and hepatitis delta virus (HDV). HDV is hepatotropic, defective RNA virus that requires obligatory HBV presence for its replication and the formation of infectious particles. About 10% of patients with chronic HBsAg-positive hepatitis infected by HDV. HDV results in coinfection (simultaneous infection of HBV and HDV) and superinfection (HDV infection with chronic hepatitis B). The natural course of the infection is characterized by rapid progression to liver cirrhosis and hepatocellular carcinoma. Diagnosis of HDV-infection is based on the detection of delta antigen, antibodies to the virus (anti-HDV IgM and IgG) and RNA HDV in serum. The effectiveness of antiviral therapy proved only on the treatment by interferon (IFN-2α and PEG-IFN-2α). The only way to protect against HDV infection is vaccination against hepatitis B.

1. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 288 с.

2. Левитан Б.Н., Дедов А.В. Дельта-гепатит. Астрахань: АГМА, 2001. 104 с.

3. Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ФГОУ ВУНМЦ Роздрава, 2003. 384 с.

4. Яшина Т.Л., Фаворов М.О., Шахгильдян И.В. и др. Распространение маркёров гепатита В и дельта среди населения регионов, контрастных по уровню заболеваемости // Вопросы вирусол. 1992. № 4. С. 194–196.

5. Abbas Z., Qureshi M., Hamid S. et al. Hepatocellular carcinoma in hepatitis D: Does it differ from hepatitis B monoinfection? // The Saudi J. Gastroenterol. 2012. Vol. 18. P. 18–22.

6. Buti M., Homs M., Rodriguez-Frias F. et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study // J. Vir. Hepat. 2011. Vol. 18. P. 434–442.

7. Delfino C., Eirin M., Berini C. et al. HDAg-L variants in covert hepatitis D and HBV occult infection among Amerindians of Argentina: new insights // J. Clin. Virol. 2012. Vol. 54. P. 223–228.

8. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection // J. Hepatol. 2012. Vol. 57. P. 167–185.

9. Einav S., Glenn J. Prenylation inhibitors: a novel class of antiviral agents // J. Antimicrobial. Chemother. 2003. Vol. 52. P. 883–886.

10. Farci P., Niro G. Clinical features of hepatitis D // Semin. Liver. Dis. 2012. Vol. 32. P. 228–236.

11. Gomes-Gouve M., Soares M., Bensabath G. et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region // J. Gen. Virol. 2009. Vol. 90. P. 2638–2643.

12. Hughes S., Wedemeyer H., Harrison P. Hepatitis delta virus // Lancet. 2011. Vol. 378. P. 73–85.

13. Ivaniushina V., Radjef N., Alexeeva M. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia // J. Gen. Virol. 2001. Vol. 82. P. 2709–2718.

14. Kozhanova T., Klushkina V., Isaeva О. et al. Prevalence of hepatitis delta virus infection in Tyva Republic, Russian Federation / EASL Monothematic Conference: Delta Hepatitis, 2010, Istanbul, Poster Board Number 58.

15. Lamers M., Kirgiz O., Heidrich B. et al. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials // Antiviral. Ther. 2012. Vol. 17. P. 1029–1037.

16. Liaw Y., Kao J., Piratvisuth T. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update // Hepatol. Int. 2012. Vol. 6. P. 531–561.

17. Olivero A., Smedile A. Hepatitis Delta virus diagnosis // Semin. Liver. Dis. 2012. Vol. 32. P. 220–227.

18. Pascarella S., Negro F. Hepatitis D virus: an update // Liver Int. 2011. Vol. 31. P. 7–21.

19. Philipp T., Durazzo M., Trautwein C. et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D // Lancet. 1994. Vol. 344. P. 578–581.

20. Rizzetto M. Hepatitis D: Thirty years after // J. Hepatol. 2009. Vol. 50. P. 1043–1050.

21. Rizzetto M., Alessia C. Epidemiology of Hepatitis D // Semin. Liver. Dis. 2012. Vol. 32. P. 211–219.

22. Rizzetto M., Canese M., Aricoo S. et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers // Gut. 1977. Vol. 18. P. 997–1003.

23. Roche B., Samuel D. Liver transplantation in delta virus infection // Semin. Liver. Dis. 2012. Vol. 32. P. 245–255.

24. Schulze A., Schieck A., Gähler C. et al. Preclinical studies on Myrcludex B, a novel Hepatitis B virus (HBV)-envelope protein derived entry inhibitor // Z. Gastroenterol. 2010. Vol. 48. P. 40–43.

25. Su C., Huang Y., Huo T. et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients // Gastroenterol. 2006. Vol. 130. P. 1625–1635.

26. Wedemeyer H. Hepatitis D revival // Liver Int. 2011. Vol. 31. P. 140–144.

27. Wedemeyer H., Manns M. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead // Nat. Rev. Gastroenterol. Hepatol. 2010. Vol. 7. P. 31–40.

28. Wedemeyer H., Yurdaydin C., Dalekos G. et al. Peginterferon plus Adefovir versus either drug alone for hepatitis delta // NEJM. 2011. Vol. 364. P. 322–331.

29. Ying Y., Ling Z. The perinatal vertical transmission of hepatitis delta virus infection between gravida and fetus // J. Neonatol. 1997. Vol. 5. P. 25–30.

30. Yurdaydin C. Treatment of chronic delta hepatitis // Semin. Liver. Dis. 2012. Vol. 32. P. 237–244.

31. Yurdaydın C., Idilman R., Bozkaya H. et al. Natural history and treatment of chronic delta hepatitis // J. Viral Hepat. 2010. Vol. 17. P.749–756.